Watch HHS Deputy Secretary & CMS Director of Medicare Chris Klomp on Administration's Pharma Pricing Policies

Virtual Pharma Pricing Summit Post-Conference Video Archive Now Available
  • Virtual Online Archived Video
  • Covering Tariffs, Most Favored Nation, TrumpRX, Direct to Consumer, Direct to Employer, Role of CMS & CMMI: GENEROUS, GLOBE, GUARD & BALANCE Models, IRA Medicare Drug Price Negotiations, Price Reporting, FDA Regulation, Medicaid Rebates, Medicare Fair Price, 340B and PBMs
  • Media Partners: Harvard Health Policy Review, Health Affairs and Inside Health Policy
  • Held June 16-19, 2026
  • www.pharmapricingsummit.com
PRESS RELEASE
Phone: 800-503-7414
Email: reginfo@hcconferences.com
Website: www.pharmapricingsummit.com
PURCHASE ACCESS TO THE ARCHIVE
Click Here to purchase access.

SUMMIT AGENDA
Click here to view the Agenda




WATCH VIDEO FIRESIDE CHAT WITH HHS/CMS LEADER CHRIS KLOMP
& FORMER CMS/FDA LEADER MARK MCCLELLAN
Mark McClellan, MD, PhD
Director, Robert J Margolis Center for Health Policy, Medicine and Health Policy, Duke University; Former CMS Administrator and FDA Commissioner (GW Bush), Washington, DC		 Chris Klomp, MBA
Chief Counselor, US Department of Health and Human Services; Director of Medicare and Deputy Administrator, Centers for Medicare & Medicaid Services, Washington, DC

WASHINGTON DC USA -- HEALTHCARE UPDATE NEWS SERVICE™ -- JUNE 29, 2026: The Virtual Pharmaceutical and Medical Device Pricing and Payment Transformation Summit was held on June 16-19, 2026 as a purely virtual online event broadcast live and will remain available in video archive for 9 months. The Summit covered the following matter relevant to pharmaceutical and medical device companies: Tariffs, Most Favored Nation, TrumpRX, Direct to Consumer, Direct to Employer, Role of CMS & CMMI: GENEROUS, GLOBE, GUARD & BALANCE Models, IRA Medicare Drug Price Negotiations, Price Reporting, FDA Regulation, Medicaid Rebates, Medicare Fair Price, 340B and PBMs.

CMS/CMMI KEYNOTE SPEAKERS

John Brooks, JD, MBA
Deputy Administrator and the Chief Policy and Regulatory Officer, CMS; Former HHS Senior Advisor for Drug Pricing Reform; Former White House Health Policy Advisor, Washington, DC
Chris Klomp, MBA
Chief Counselor, US Department of Health and Human Services; Director of Medicare and Deputy Administrator, Centers for Medicare & Medicaid Services, Washington, DC
Abe Sutton, JD
Director, CMS Center for Medicare and Medicaid Innovation; Former Policy Advisor at the Domestic Policy Council, The White House (Trump), Washington, DC

KEYNOTE SPEAKERS

Liz Fowler, PhD, JD
Scholar, Johns Hopkins Bloomberg School of Public Health; Former Director, CMS CMMI (Biden); Former Special Assistant to President Obama, Washington, DC
Mark McClellan, MD, PhD
Director, Robert J Margolis Center for Health Policy, Medicine and Health Policy, Duke University; Former CMS Administrator and FDA Commissioner (GW Bush), Washington, DC
Nicholas Minter, MPP
Acting Director, Seamless Care Models Group, CMS Innovation Center; Former Senior Budget Analyst, HHS; Former Program Examiner, OMB, Silver Springs, MD

Mickey Morgan
Director, CMS Division of Pharmacy, Center for Medicaid and CHIP Services, Centers for Medicare and Medicaid Services, Washington, DC
Larisa Strawbridge, MPH
Acting Director, Medicare Drug Rebate and Negotiations Group, Centers for Medicare and Medicaid Services, Washington, DC


PURCHASE ACCESS TO THE ARCHIVE
Click Here to purchase access.

SUMMIT AGENDA
Click here to view the Agenda

PRODUCED BY


MEDIA PARTNERS






FEATURING ROUNDTABLE ON THE IMPLICATIONS OF ACTUAL AND THREATENED US PHARMA TARIFFS BY

Neena Shenai, JD
Partner, WilmerHale; Former Chief Legal Counsel and Head of Compliance for Global Trade, Medtronic; Former Trade Counsel, Ways and Means Committee, US House of Representatives, Washington, DC
Mariana P. Socal, MD, PhD, MPP, MSc
Associate Professor, Bloomberg School of Public Health and Carey Business School, Johns Hopkins University; Co-author, "Comparative Approaches to Drug Pricing" and "Tariffs as a Hidden Tax: Price Pass-Through in Multi-Stage Supply Chains", Baltimore, MD
Arun Venkataraman, MA, JD
Partner, Covington; Former Assistant Secretary of Commerce, US and Foreign Commercial Service, International Trade Administration; Former Counselor to the Secretary, US Department of Commerce, Washington, DC
Joshua M. Sharfstein, MD
Vice Dean, Johns Hopkins Bloomberg School of Public Health; Former Secretary, Maryland's Health Department; Former Principal Deputy Commissioner, US FDA, Baltimore, MD (Moderator)

TARIFF COMPLIANCE ISSUES FOR PHARMACEUTICALS AND MEDICAL DEVICE COMPANIES BY

Shani Harmon Alexander, MS, JD
Senior Trade Counsel, Gilead; Former Director, Legal Manufacturing, Organon, Washington, DC
Galina Free, MSc
Head of Trade Compliance, Danaher; Former Global Tax and Customs, Cisco, Bellevue, WA
Roger McCrary, JD
Senior Trade Counsel, Becton Dickinson; Former Vice President of Global Compliance, Momentive; Former Global Trade Compliance Program Leader, Medtronic, Oakland, MI
Neena Shenai, JD
Partner, WilmerHale; Former Chief Legal Counsel and Head of Compliance for Global Trade, Medtronic; Former Trade Counsel, Ways and Means Committee, US House of Representatives, Washington, DC (Moderator)

AN OVERVIEW OF US PHARMA & DEVICE MOST FAVORED NATIONS/INTERNATIONAL REFERENCE PRICING INITIATIVES BY

Lanhee Chen, PhD
Fellow, Hoover Institution, Stanford; Former Counselor, HHS; Author, "Alternatives to Government-Imposed Price Controls to Lower US Drug Prices", Stanford, CA
Liz Fowler, PhD, JD
Scholar, Johns Hopkins Bloomberg School of Public Health; Former Director, CMS CMMI (Biden); Former Special Assistant to President Obama, Washington, DC
James Robinson, PhD
Schaeffer Professor of Health Economics & Director, Berkeley Center for Health Technology, University of California, Berkeley; Author, "Most Favored Nation Pricing is an Idea whose Time has Come", Berkeley, CA
Ian Spatz, MPA, JD
Principal, Rock Creek Policy Group; Former Vice President, Public Policy, Merck, Author, "Most Favored Nation Drug Pricing: Aiming at Pharma's Achilles Heel", Washington, DC
Kristi Martin, MA, MPH
Founder, Highway 136 Consulting; Former Chief of Staff for Medicare, CMS; Former Health Care VP, Arnold Ventures, Washington, DC (Moderator)

IMPLEMENTING THE CMS/CMMI BALANCE, GENEROUS, GLOBE AND GUARD MODELS BY

Cindy Cerneka, MBA
Managing Director, Helio Health Group; Former Manager Government Reporting and Commercial Rebates, Mallinckrodt Pharmaceuticals, Durham, NC
Tracy Mumpower
Director Managed Services, Helio Health Group; Former Manager, Commercial Contract Administration, King Pharmaceuticals, Bristol, VA
Joseph Skupen, CPA
Managing Director, Senior Advisor and Technical Leader, Helio Health Group; Former Director FMV Tiering Global Medical Affairs, Sanofi, Berwyn, PA
Stephanie Trunk, JD, CPS
Partner and Life Sciences Industry Group Co-Leader, ArentFox Schiff; Former Legal Counsel, Catalyst Health Solutions, Washington, DC
Chris Cobourn, MS
Managing Director and Government Programs (GP) Practice Lead, Helio Health Group, Placida, FL (Moderator)

NEW BUSINESS MODELS TO MEET PATIENTS WHERE THEY ARE BY

Peter Brensilver, MPH, JD
Senior Vice President, Chief Global Commercial Compliance, and Risk Counsel, Pfizer, New York, NY
Stefanie A. Doebler, JD
Partner and Co-Chair, Health Care Practice Group, Covington & Burling, LLP, Washington, DC
Sarah A. Franklin, JD
Partner and Vice-Chair, Life Sciences Investigations Practice, Covington & Burling, LLP; Former Attorney, US Federal Trade Commission, Washington, DC

FEATURING HOW TO ENGAGE WITH GOVERNMENT'S DIRECT-TO-CONSUMER DRUG POLICY BY

Jennifer Bragg, JD
Partner, Latham and Watkins; Former Associate Chief Counsel for Enforcement, Office of Chief Counsel, US Food and Drug Administration, Washington, DC
Sari Heller Ratican, JD, LLM
Privacy and Cybersecurity Counsel, Fenwick & West; Former Skills: FCRA, Chief Privacy Officer, Worldwide Compliance & Business Ethics, Amgen; Former Legislative Counsel, AMA, Los Angeles, CA
Jennifer Snow, MPH
Founder, Apteka Policy; Former Vice President, Market Economics, AmerisourceBergen; Former Advisor, Office of Health Insurance Exchanges, US Department of Health and Human Services, Washington, DC
Mary Kohler, JD
Founder and Principal, Kohler Health Law, PC; Former Expert Counsel, Worldwide Compliance & Business Ethics, Amgen; Former Assistant General Counsel, GSK, Los Angeles, CA (Moderator)

AND A BIO AND PhRMA UPDATE BY

John Delacourt, JD
Deputy General Counsel, Vice President Health, Regulatory & Commercial Operations, Biotechnology Innovation Organization; Former Chief Antitrust Counsel, Office of Policy Planning, FTC, Washington, DC
Julie Ritchie Wagner, JD
Senior Assistant General Counsel & Head of Global Ethics, Compliance & Enforcement Legal Policy, PhRMA; Former Senior Counsel, Office of Counsel to the Inspector General, US Department of Health and Human Services, Washington, DC

FEATURED FACULTY

Heather Banuelos, JD
Counsel, King & Spalding LLP; Former FDA Counsel, Allergan; Former Associate Chief Counsel, US Food and Drug Administration, Washington, DC
Brian A. Bohnenkamp, MHA, JD
Partner, FDA and Life Sciences, King & Spalding, Washington, DC
Catherine Brandon, JD
Partner, Arnold & Porter; Senior Counsel, Office of the Assistant Secretary for Legislation, US Department of Health and Human Services, Washington, DC
Marijo G. Bustos, MBA
Head of Government Pricing & Reimbursement, UCB; Former Director, Prometic BioProduction & BioTherapeutics & Fresenius-Kabi USA, Smyrna, GA
Victoria Corke, JD
Of Counsel, Covington & Burling; Former Supervisory Attorney Advisor, Office of the General Counsel, HHS; Former Trial Attorney, US Department of Justice, Washington, DC

John Coster, PhD, RPh
Former Director, Division of Pharmacy, & Senior Advisor, Medicare Drug Rebate & Negotiation Program, CMS, Fort Lauderdale, FL
Niels Christian Ersboll, Master at Laws
Partner and Global Co-Chair Antitrust, Arnold & Porter, Brussels, Belgium
TJ Garrigan, JD
Senior Advisor, Covington & Burling; Former Deputy Director, Division of Policy, Medicare Drug Rebate and Negotiations Group, CMS Center for Medicare, Washington, DC
Kristie Champlin Gurley, JD
Partner Covington & Burling; Former Counsel, Office of the General Counsel, CMS Division, US Department of Health and Human Services, Washington, DC
Jeffrey Handwerker, JD
Partner, Arnold & Porter; Lead Author, “HHS-OIG Guidance on Manufacturer DTC Platforms and Congressional Pushback”, Washington, DC

Erin Hertzog, JD, MPH
Partner, Manatt, Phelps & Phillips LLP; Former Attorney, Office of the General Counsel, CMS Division, US DHHS; Former Director, Health Law & Policy, Biotechnology Industry Organization, Washington, DC
Samuel Lonergan, JD
Partner, Arnold & Porter Kaye Scholer LLP, Glen Ridge, NJ
Neal Masia, PhD
Co-founder and CEO, EntityRisk, Inc.; Founder, Health Capital Group, LLC; Former Vice President, Global Economics, Pfizer; Former Analyst, US. Congressional Budget Office, Miami, FL
Joey Mattingly, PharmD, MBA, PhD
Associate Professor & Vice Chair of Research at the University of Utah College of Pharmacy; Former Special Advisor related to the Inflation Reduction Act, CMS, Park City, UT
Pari R. Mody, JD
Partner, Arnold & Porter; Coauthor, "Trump Administration Issues Executive Order To Lower Prescription Drug Costs", Washington, DC

William Newton
Associate Editor/Senior Writer, 340B Report; Senior Healthcare Reporter, GlobalData Healthcare, Washington, DC
Sayeh Nikpay, MPH, PhD
Associate Professor, School of Public Health, University of Minnesota; Lead Author, "When Safety-Net Programs Compete: Medicaid, 340B, and the Battle Over Drug Discounts", Minneapolis, MN
Lindsay Pronley
Director Managed Services, Life Science Revenue Management, Government Pricing & Commercial Contacting, Helio Health Group, Milwaukee, WI
Nikki Reeves, JD
Partner and Co-chair, Life Sciences and Healthcare Industry Group, King & Spalding, Washington, DC
Avik S. A. Roy
Co-Founder & Chairman, The Foundation for Research on Equal Opportunity; Chief Strategy Officer, Strive; Former Advisor, Presidential Campaigns of Marco Rubio, Rick Perry, and Mitt Romney, Austin, TX

Gillian M. Russell, JD
Counsel, FDA & Life Sciences Practice, King & Spalding; Former Consultant, Corporate Executive Board, Washington, DC
Valinda Rutledge, MBA
Executive Vice President, Policy and Advocacy, America's Physician Groups; Former Group Director, Patient Care Model Group and BPCI Lead, CMS, Washington, DC
William Sarraille, JD
Select Counsel, Rare Access Action Project (RAAP); Facioscapulohumeral Muscular Dystrophy (FSHD) Society; and AIDS Drug Assistance Programs (ADAPs); Former Partner, Sidley Austin, Washington, DC
John Shakow, JD
Pharmaceutical Government Price Reporting Expert; Partner, FDA & Life Sciences Practice, King & Spalding LLP, Washington, DC
Nick Shipley
Founder, Cronus Consulting; Former EVP, BIO; Former VP, PhRMA; Former Legislative Director, US House of Representatives, Washington, DC

SUMMIT REGISTRATION

For Summit registration information, visit www.pharmapricingsummit.com/registration/, email reginfo@hcconferences.com, or call 800-503-7414.


FOR E-MAIL ADDRESS CHANGE, ADD OR DELETE REQUESTS:

For changes or additions, please email your request to: listmgr@HealthcareUpdateNewsService.com.

For automatic removal of your e-mail address, please click the "SafeUnsubscribe" link located in the footer of this message below.